PMC8795764_01
Time axis. Time axis of treatment of primary and recurrent tumours.
fonc-11-810708-g001.jpg
PMC8795764_01_fonc-11-810708-g001.jpg
f1
Diagnosis and treatment of the patient is shown in  Figure 1 .
Computed tomography findings. Pelvic computed tomography of primary tumour (A-D). (A) Plain scan. (B) Arterial phase. (C) Venous phase. (D) Excretion phase. Pelvic computed tomography of recurrent tumour (E-H). (E) Plain scan. (F) Arterial phase. (G) Venous phase. (H) Excretion phase.
fonc-11-810708-g002.jpg
PMC8795764_01_fonc-11-810708-g002.jpg
f2
CEA; glycoprotein antigen 199, CA199; glycoprotein antigen 724, CA724; keratin 19 fragment, CYFRA; neuron enolase, NSE; beta subunit of human chorionic gonadotropin hormones, beta-HCG; testosterone, TESTO; prolactin, PRL; progesterone, PROG; luteinizing hormone, LH; follicle stimulating hormone, FSH and estradiol, E2) were normal. CT of the pelvic cavity showed a heterogeneous mass in the left scrotum, which was considered malignant because the mass is obviously enhanced in the arterial phase ( Figure 2 ). IMT ( Figure 2 ). Informed consent was obtained from the patient to perform an extensive tumorectomy of the left lower abdominal wall.
Histological findings. Hematoxylin and Eosin staining of paraffin-embedded sections. (A) Magnification x 40. (B) Magnification x 100. (C) Magnification x 400.
fonc-11-810708-g003.jpg
PMC8795764_01_fonc-11-810708-g003.jpg
f3
The postoperative pathological examination revealed abnormal testis parenchymal structure with large numbers of infiltrating lymphocytes and plasma cells, lymphatic follicles, and proliferating fibroblasts and myofibroblasts; additionally, scattered R-S cells could be seen in some areas ( Figure 3 ).